Find in Library

The COVID-19 pandemic has emerged as one of the major global health crises of recent times. It has posed adverse consequences for people with mental illnesses with its potential to infect patients with existing psychiatric disorders on psychotropic drugs and additionally, spawning psychiatric symptoms in patients infected with COVID-19. To add to the miseries, there have been a multitude of experimental treatments in the form of antivirals, immune-modulators, corticosteroids, etc., which can have serious interactions with psychotropic drugs. In this review, we intend to provide recommendations for pharmacotherapy to address the neuropsychiatric morbidity in COVID-19 patients.